Drug intelligence / Profile preview

LEM-S403

Development stage: Preclinical
Lead developer: Lemonex
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics

Overview

LEM-S403 is a dual-acting RNA immuno-oncology drug candidate developed for the treatment of solid tumors. It is being developed by Lemonex and utilizes the proprietary DegradaBALL nanoparticle-based drug delivery platform, which enables targeted delivery of oligonucleotide therapeutics such as siRNA or mRNA. While detailed mechanistic information has not been disclosed, it is described as an immunotherapy with a novel modality distinct from traditional small molecules or antibodies. The drug remains in preclinical development and has not yet entered clinical trials[1][2][4][7][9].

Beyond the preview

Go deeper on LEM-S403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEM-S403.

Explore the full profile